GlaxoSmithKline submits regulatory application for UMEC/VI

A.B. | ShareCast | 18 Dec, 2012 12:05 - Updated: 12:58 | | |

needle

Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for UMEC/VI medicine, used to treat chronic obstructive pulmonary disease (COPD).

UMEC/VI is an investigational once-daily LAMA/LABA combination medicine. It includes properties, umeclidinium bromide --- a long-acting muscarinic antagonist (LAMA)--- and vilanterol, a long-acting beta2 agonist which is administered using the Ellipta inhaler.

The application proposes the proprietary name Anora Ellipta and has been submitted to the US Food and Drug Administration for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.

Applications for UMEC/VI are also planned in the European Union and in other countries next year.

FSTE 100 company GSK is a leading research-based pharmaceutical and healthcare company.

Theravance is a biopharmaceutical company which collaborates with a number of pharmaceutical organisations.

RD

More news

19:19 Intesa SanPaolo studying bid for all of Coutts

18:17 Russian and US foreign ministers to meet on Sunday

Russia’s foreign minister, Sergei Lavrov, and his US counterpart, US Secretary of State John Kerry, were due to hold a bilateral meeting on Sunday on the sidelines of the current negotiations on Iran’s nuclear programme, Interfax reported.

18:09 Savoy sales and profits drop nearly 3%

The Savoy hotel in London saw sales and profits plummet last year by almost 3% to £58.5m.

18:23 German foreign minister urges talks with Putin, as fighting in Ukraine continues

German foreign minister Frank-Walter Steinmeier has urged further discussions with Russian President Vladimir Putin after speculating that Russia may seek to disjoin Ukraine by backing eastern separatists.

17:47 Four Seasons considers options as debt mounts and earnings fall

UK care home group Four Seasons has appointed Blackstone Advisory Partners to assess its options amid reports the company's owner, Terra Firma, is looking at new avenues to tackle sliding earnings and mounting debts.

17:42 Chinese policy-makers to cut rates again, source claims

Chinese authorities are reportedly set to once again cut their interest rates amid widespread concerns over a drop in prices.

17:27 Week ahead: US data and OPEC summit in focus

The coming week will see a raft of economic indicators released Stateside in a holiday-shortened week, due to the Thanksgiving Day holiday. Wednesday, in particular, will be very informative, with no less than seven important economic reports due out, including the latest readings on orders for durable goods and the Chicago PMI.

17:05 Telecom group to launch attack on BT broadband 'monopoly'

A group of telecom firms have reportedly banded together to denounce the market “monopoly” held by BT.

16:58 US close: Stocks rally amid positive news from Europe and China

US stocks rallied on Friday, as oil and metal prices rose after a surprise rate cut from China’s central bank.

17:37 Sunday share tips: Centrica, Concha, UDG Healthcare

Investors should avoid Centrica shares, Questor advised in the Sunday Telegraph. The British Gas owner has been hit by political uncertainty following Labour leader Ed Miliband's pledge to freeze energy prices, as well as warmer weather and falling oil prices at its exploration business. After three profit warnings in the past year the dividend is starting to look shaky, especially as political pressure makes it hard to cut capital spending. Shareholders are exposed to dividend cuts, a falling share price and the prospect of debt costs rising.

Advertising

HIGHLIGHTS

russia putin
German foreign minister urges talks with Putin, as fighting in Ukraine continues

Steinmeier speculates that Russia may seek to disjoin Ukraine by backing eastern separatists.

VIDEOS

Support and resistance levels Support and resistance levels 21th november 2014
REGISTER NOW!